Daniel Kennedy


Post Doctoral Fellowship, Harvard Medical School
PhD, State University of New York at Buffalo
MS, Emory University


Daniel R. Kennedy received his B.S. and M.S. degrees in Chemistry from Emory University and his Ph.D. in Molecular Pharmacology and Experimental Therapeutics from the State University of New York at Buffalo–Division of the Roswell Park Cancer Institute. Before joining Western New England University, he instructed a wide variety of science courses at Emmanuel College while completing a post-doctoral fellowship at Harvard Medical School in the areas of hemostasis and thrombosis.

At WNE he has instructed in 12 distinct courses, including every offering of Principles of Pharmacology and Pathophysiology, He was named an Emerging Teaching Scholar by the American Association of Colleges of Pharmacy in 2017 and has mentored over 50 PharmD and graduate students on research projects.

Dr. Kennedy’s current laboratory research focus utilizes high throughput screening methodologies to identify broad spectrum thiol isomerase inhibitors and explore their roles in cancer, thrombosis and cancer induced thrombosis. This work has been funded by the NIH and is currently undergoing a Phase II clinical trial in collaboration with Harvard Medical School. Additional projects and collaborations include Baystate Medical Center, the University of Kentucky and the University of Reading (UK).

Beyond the laboratory, Dr. Kennedy has explored multiple projects in the scholarship of teaching and learning and best practices in pharmacy education, publishing over 15 manuscripts in these areas and serving as an Editorial Board Member of the American Journal of Pharmaceutical Education. He is an active member of the American Society of Pharmacology and Experimental Therapetuics, International Society of Thrombosis and Hemostasis and the American Assocation of Colleges of Pharmacy, the latter of which he has held many leadership positions in throughout his career, including Chair of the Biological Sciences Section.

Scholarly Works

Select Peer-Reviewed Articles: (Last 5 Years)

* indicates student co-author

Laboratory Based

Holbrook LM, Keeton S, Sasikumar P, Nock S, Gelzinis J, Brunt E, Ryan S, *Pantos MM, *Verbetsky C, Gibbins JM, and Kennedy DR.  Zafirlukast is a broad-spectrum thiol isomerase inhibitor that inhibits thrombosis without altering bleeding times. British Journal of Pharmacology. – 2021;1–14. https://doi.org/10.1111/bph.15291

Krajewski D, Polukort SH, Gelzinis J, *Rovatti J, *Kaczinski E, *Galinski C, *Pantos MM, Shah NN, Schneider SS, Kennedy DR and Mathias CB.   Protein disulfide isomerase inhibition regulates mast cell function conferring protective effects to ingested allergens.  Frontiers in Immunology - Front. Immunol. 11:606837.doi: 10.3389/fimmu.2020.606837

*Dutra B, Mora MC, *Gerhardson TI, *Sporbert B, Dufresne A, Bittner K, Lovewell C, Rust MJ, Tirabassi M, Masi L, Lipkens B, Kennedy DR.  A Novel Macro-scale Acoustic Device for Blood Filtration.  Journal of Medical Devices – 2018 12(1) 011008.

Bekendam RH, Bendapudi P, Lin, L, Nag PP, Pu J, Kennedy DR, *Feldenzer A, Chiu J, Cook KM, Furie B, Huang M, Hogg PJ, Flaumenhaft R. A Substrate-Driven Allosteric Switch that Enhances PDI Catalytic Activity. Nature Communications – 2016 Aug 30;7:12579. doi: 10.1038/ncomms12579

*Galinski CN, Zwicker, JI and Kennedy DR.   Revisiting the mechanistic basis of the French Paradox: Red wine inhibits the activity of protein disulfide isomerase in vitro, Thrombosis Research – 2016 137(1):169-173

Non-laboratory based

Kennedy DR, Clapp P, DeLuca Jl, Filtz TM, Kroon L, Lamberts JT, Oliphant CM, Prescott WA, Ray SD. Enhancing Pharmacy Faculty Well-Being and Productivity while Reducing Burnout.  American Journal of Pharmaceutical Education – Paper in Press

*Pantos MM, Kennedy DR, Nemec EC.  Remimazolam: a novel option for procedural sedation in high risk patients. Journal of Pharmacy Practice – Paper in Press

*Dias ML, *Armstrong KJ, *Pantos MM, Spooner JS, Kennedy DR.  Examining Course Credits, Placement, and Integration of Pathophysiology and Anatomy and Physiology within PharmD Curriculum. American Journal of Pharmaceutical Education. 2020, 84 (11) 8025

Kennedy DR, Harrell TK, Lodise NM, Mattingly TJ II, Norenberg JP, Ragucci K, Ranelli P, Stewart AS. Current Status and Best Practices of Shared Governance within US Pharmacy Programs.  American Journal of Pharmaceutical Education – 2020, 84 (7) 7281

Kennedy DR - The Effect of Banning Computers on Exam Performance in a First-Year Pathophysiology Class. American Journal of Pharmaceutical Education – 2019, 83 (10) 7535

*Vuernick EL, *Josefiak KF, Spooner JJ, and Kennedy DR.  Non-terminal Degree Offerings in US Pharmacy Programs. American Journal of Pharmaceutical Education – 2019 83(7) Article 6917.

Kennedy DR.  Redesigning a Principles of Pharmacology Course to Promote Active Learning. American Journal of Pharmaceutical Education – 2019 83(5) Article 6782.

Hammer DP, Bynum LA, Carter J, Hagemeier NE, Kennedy DR, Khansari P, Stamm P, Crabtree B. Revisiting Faculty Citizenship. American Journal of Pharmaceutical Education – 2019 83(4) Article 7378.

*DiPietro PA, *Longo S, Welch BE, Kennedy DR, and Nemec EC.  Current Practices of Awarding Graduation Honors within Doctor of Pharmacy Degree Programs.  American Journal of Pharmaceutical Education – 2017 81(4) Article 69.

Spooner JJ and Kennedy DR.  An Elective Course to Foster Interest in Academic Pharmacy Career Opportunities.  American Journal of Pharmaceutical Education – 2017 81(1) Article 13

*Scalise AA, *Lezaja GS, Nemec EC, Spooner JS, and Kennedy DR. Valued Characteristics of Community Pharmacy Residency Applicants. Journal of the American Pharmacists Association. 2016 56(6) pp. 643-648 doi: 10.1016/j.japh.2016.06.011